PRKCA and gastric cancer: In summary, this study further investigated DADS as a novel agonist that reduces RORα/β-catenin signaling, inhibits GC cell invasion and EMT, and enhances 5-FU chemosensitivity via PKCα/RORα mediated by SR1078 and TPA.